Recent SEC filings show that Seagen, recently bought out by Pfizer, will share patent rights to experimental cell therapies with Gracell Biotechnologies. The deal will see Gracell performing clinical and preclinical testing on certain cell therapies, the identities of which have yet to be revealed. Additionally, five of the therapies will be taken to market by Gracell.
According to Max Gelman, “Gracell, meanwhile, has forged a path in the CAR-T space with backing from Temasek, Lilly Asia Ventures, OrbiMed and others. The startup, founded in 2017 and based out of China, is developing at least four CAR-Ts and its lead program, targeting BCMA and CD19, is expected to begin a Phase Ib/II study for relapsed/refractory multiple myeloma in the US before the end of June.”
To read more, click here.
(Source: Endpoints News, March 16th, 2023)